The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | New therapies in multiple myeloma
Rafael Fonseca
• 4 Dec 2015
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about the new therapies in multiple myeloma, such as ixazomib, elotuzumab, daratumumab and Isatuximab.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.
